Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 10Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Salivary Gland Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Docetaxel 7Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Biopsy 3Vorinostat 2Trastuzumab 2Taxes 2Radiotherapy 2Polymerase Chain Reaction 2Immunohistochemistry 2Gene Expression Profiling 2Flow Cytometry 2zanidatamab 1vandetanib 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1spartalizumab 1sargramostim 1pembrolizumab 1larotrectinib 1fluoromisonidazole 1entrectinib 1entinostat 1ceralasertib 1alectinib 1X-Ray Therapy 1Thalidomide 1Specimen Handling 1Rubidium-82 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × zanidatamab × Breast × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡